ImmunoGen Inc., a Waltham-based biotechnology company, announced in a Tuesday press release that Gregory D. Perry, executive vice president and chief financial officer, has provided notice of his intention to resign from the company to pursue other interests, effective Sept. 13.
“I sincerely appreciate Greg’s service to ImmunoGen over the four years we have worked together,” Daniel M. Junius, ImmunoGen president and chief executive, said in a statement. “On behalf of the company, I thank Greg for his many contributions and wish him well in his future endeavors.”
ImmunoGen is initiating a search to hire Perry’s replacement. In the interim, Junius will be the company’s acting chief financial officer.
ImmunoGen looks to develop novel anticancer therapeutics by using its proprietary antibody-drug conjugate technology.
Earlier this year, federal regulators approved a highly anticipated breast cancer drug that will be sold under the brand name Kadcyla, a Globe story reported in February. Key components of Kadcyla were developed by ImmunoGen, including a proprietary cancer-killing agent and a “linker” that binds the medicine to a type of chemotherapy drug.
Kadcyla is marketed in the US by the Genentech unit of Swiss drug maker Roche AG.